Select Your Region
Global
A Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
- Cancer
Please note that the recruitment status of the trial at your site may differ from the overall study status because some study sites may recruit earlier than others.
Trial Status:
Completed
This trial runs in
Cities
- Aalborg
- Aarhus
- Adelaide
- agios-pavlos
- Amsterdam
- Arezzo
- Arizona
- Athens
- Badalona
- Baia Mare
- Barcelona
- Bari
- Barrie
- Basel
- Bayrut
- Bellinzona
- Bern
- Bilbo
- Bogotá
- Bologna
- Box Hill
- Braga
- Bratislavský kraj
- Brno
- Bruxelles
- Budapest
- Buenos Aires
- Calgary
- Cardiff
- Catania
- Ceará
- Chieti
- Chur
- Cluj-Napoca
- Coimbra
- Cork
- Craiova
- Cremona
- Cáceres
- Córdoba
- Dresden
- Dublin
- Edmonton
- Erlangen
- Florești
- Garran
- geneva
- Girona
- Groningen
- Guadalajara
- Gurugram
- Göttingen
- Halifax
- Halle (Saale)
- Hannover
- Heidelberg
- Herlev
- Hlavní město Praha
- Hobart
- Innsbruck
- Inverness
- Jette
- Kaunas
- Kifisia
- København
- L'Hospitalet de Llobregat
- La Laguna
- lapkaman
- Lazio
- Leicester
- Leuven
- Linz
- Lisboa
- Lombardia
- London
- Lublin
- Lugo
- luik
- Luzern 16
- Lübeck
- Maastricht
- macquarie-park
- Madrid
- Manresa
- Marousi
- Meldola
- Milano
- Modena
- monserrato
- Moscow Oblast
- Murcia
- Málaga
- Mönchengladbach
- München
- Münster
- nan-jing-shi
- Napoli
- New Delhi
- new-town
- Ottawa
- Ourense
- Oviedo
- Padova
- Palma
- Pamplona
- Paraná
- Pireas
- Plovdiv
- Porto
- Poznań
- Randwick
- Reggio Emilia
- Rio Grande do Sul
- Riyadh
- Roma
- Sabadell
- Salzburg
- San Giovanni Rotondo
- Sanatorio San Luigi
- sant-andreu-de-la-barca
- Santiago de Compostela
- Sevilla
- Sofia
- South Brisbane
- St Leonards
- Sutton
- Szeged
- Szolnok
- São Paulo
- Tainan City
- Tallinn
- Taoyuan City
- Terni
- Thermi
- Thessaloniki
- Timișoara
- Toledo
- Tuscany
- Tübingen
- Udine
- Ulm
- Utrecht
- València
- Verona
- Vilnius
- Waratah
- Warszawa
- Wien
- Winterthur
- Zagreb
- Żory
Trial Identifier:
NCT02928406 2016-002625-11 MO29983
Trial Summary
This Phase IIIb, multicenter study will assess the safety of atezolizumab as second- to fourth-line treatment for participants with locally advanced or metastatic urothelial or non-urothelial cancer of the urinary tract in addition to evaluate the efficacy of atezolizumab and potential tumor biomarkers associated with atezolizumab.
Hoffmann-La Roche
Sponsor
Phase 3
Phase
NCT02928406, MO29983, 2016-002625-11
Trial Identifier
Atezolizumab
Treatments
Urinary Tract Cancer
Condition
Official Title
An Open Label, Single Arm, Multicenter, Safety Study of Atezolizumab in Locally Advanced or Metastatic Urothelial or Non-Urothelial Carcinoma of the Urinary Tract
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Participants with histologically documented locally advanced (tumor [T] 4b, any node [N]; or any T, N 2-3) or metastatic (M1, Stage IV) urothelial or non-urothelial carcinoma of the urinary tract
- Participants with measurable and/or non-measurable disease according to RECIST v1.1
- Participants must have progressed during or following treatment with at least one prior (and not more than 3) treatments for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
- If available, a representative formalin-fixed paraffin-embedded (FFPE) tumor specimen block should be submitted
- Eastern cooperative oncology group (ECOG) performance status 0, 1 or 2
Exclusion Criteria
- Treatment with more than three prior lines of systemic therapy for inoperable, locally advanced or metastatic urothelial or non-urothelial carcinoma of the urinary tract
- Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 4 weeks prior to study treatment initiation
- Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were not on active drug in that prior trial are eligible
- Participants who were in another clinical trial with therapeutic intent within 4 weeks of study treatment initiation but were in the follow-up phase of that prior trial and had stopped receiving active drug 4 or more weeks before study treatment initiation are eligible
- Malignancies other than the one studied in this protocol within 5 years prior to Cycle 1, Day 1
- Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol
- Significant renal disorder indicating a need for renal transplant
For the latest version of this information please go to www.forpatients.roche.com